How it works

Affibody^® molecules are a novel class of small, engineered proteins with characteristics that may offer substantial advantages over monoclonal antibodies, antibody fragments, small molecules and peptides. The company has created a large library consisting of more than ten billion Affibody® molecules, all with unique binding sites, from which binders to given targets are selected. The Affibody^® platform is uniquely suited for radiotherapy applications. These small (6 kDa) engineered proteins can be attached to radioactive agents, enabling selective targeting of surface proteins on tumor cells. Our Albumod^® linker technology enables association with serum albumin resulting in an optimized biodistribution, allowing the radioactive agent to emit its radiation with high precision to tumors. In addition, Affibody^® molecules have demonstrated clinical value as efficacious disease modifying agents in immunology and inflammation.

Advantages

Affibody’s technology platform offers several key advantages over current approaches, including:

Broad range of targets

To date, approved RLT drugs have been small molecules or peptides whose binding characteristics limit the addressable target space. Affibody® molecules enable highly selective, high affinity targeting of a broader range of tumor-associated proteins, opening the door to new treatments for solid tumors beyond those currently addressed by RLTs.

Tunable biodistribution and long tumor retention

Our Albumod^® linker technology enables association with serum albumin resulting in an optimal biodistribution, allowing the radioactive agent to emit its radiation with high precision to tumors over an extended period of time.

Radioisotope and chelator agnostic

Site specific modifications create flexibility to attach long-acting isotopes such as lutetium-177, actinium-225 or terbium-161.

Developability

Affibody^® molecules have robust biophysical properties, enabling use of standard scale-up and manufacturing processes. Affibody^® molecules are highly stable, which facilitates radioconjugation.

A strong and diversified patent portfolio

An active patent strategy is a precondition for protecting the value of the scientific advances that Affibody delivers. The company has successfully established strong intellectual property protection for its drug candidates in all major geographical markets including the US, the EU, Japan, and other countries.

Our patent portfolio

• Affibody has a portfolio encompassing 38 patent families (a patent family is a group of patents and patent applications in different countries that have the same origin).

Our patent strategy

• Concurrent with the scientific advances made in Affibody’s research and development activities, the company regularly submits patent applications to ensure intellectual property and secure potential future earnings.

Our patent longevity

• Affibody’s patents and patent applications provide intellectual property protection into the 2040’s.

Company trademarks

Affibody
“Affibody” is registered in the US, EU, Japan, Australia, Canada, China, Republic of
Korea, Switzerland, and United Kingdom.

Albumod
“Albumod” is registered in the US, EU, Japan, China, and United Kingdom.

Company logotype
The Affibody logotype is registered in the US, EU, Japan, Australia, China, Republic of Korea, Switzerland, and United Kingdom, with a pending application in Canada.